SVB Securities analyst Mani Foroohar maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $143.00. The company’s shares closed last Friday at $229.65.
According to TipRanks, Foroohar is an analyst with an average return of -14.9% and a 38.29% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Ionis Pharmaceuticals, and Bluebird Bio.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alnylam Pharma with a $247.33 average price target, implying a 7.70% upside from current levels. In a report released on January 11, BMO Capital also maintained a Hold rating on the stock with a $200.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $264.31 million and a GAAP net loss of $405.92 million. In comparison, last year the company earned a revenue of $187.63 million and had a GAAP net loss of $204.51 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY: